β1-Blockade Prevents Post-Ischemic Myocardial Decompensation Via β3AR-Dependent Protective Sphingosine-1 Phosphate Signaling

Alessandro Cannavo, Giuseppe Rengo, Daniela Liccardo, Andres Pun, Ehre Gao, Alvin J. George, Giuseppina Gambino, Antonio Rapacciuolo, Dario Leosco, Borja Ibanez, Nicola Ferrara, Nazareno Paolocci, Walter J. Koch

Research output: Contribution to journalArticle

Abstract

Background Although β-blockers increase survival in patients with heart failure (HF), the mechanisms behind this protection are not fully understood, and not all patients with HF respond favorably to them. We recently showed that, in cardiomyocytes, a reciprocal down-regulation occurs between β1-adrenergic receptors (ARs) and the cardioprotective sphingosine-1-phosphate (S1P) receptor-1 (S1PR1). Objectives The authors hypothesized that, in addition to salutary actions due to direct β1AR-blockade, agents such as metoprolol (Meto) may improve post–myocardial infarction (MI) structural and functional outcomes via restored S1PR1 signaling, and sought to determine mechanisms accounting for this effect. Methods We tested the in vitro effects of Meto in HEK293 cells and in ventricular cardiomyocytes isolated from neonatal rats. In vivo, we assessed the effects of Meto in MI wild-type and β3AR knockout mice. Results Here we report that, in vitro, Meto prevents catecholamine-induced down-regulation of S1PR1, a major cardiac protective signaling pathway. In vivo, we show that Meto arrests post-MI HF progression in mice as much as chronic S1P treatment. Importantly, human HF subjects receiving β1AR-blockers display elevated circulating S1P levels, confirming that Meto promotes S1P secretion/signaling. Mechanistically, we found that Meto-induced S1P secretion is β3AR-dependent because Meto infusion in β3AR knockout mice does not elevate circulating S1P levels, nor does it ameliorate post-MI dysfunction, as in wild-type mice. Conclusions Our study uncovers a previously unrecognized mechanism by which β1-blockers prevent HF progression in patients with ischemia, suggesting that β3AR dysfunction may account for limited/null efficacy in β1AR-blocker–insensitive HF subjects.

Original languageEnglish (US)
Pages (from-to)182-192
Number of pages11
JournalJournal of the American College of Cardiology
Volume70
Issue number2
DOIs
StatePublished - Jul 11 2017

Fingerprint

Metoprolol
Heart Failure
Lysosphingolipid Receptors
Cardiac Myocytes
Knockout Mice
Down-Regulation
sphingosine 1-phosphate
HEK293 Cells
Adrenergic Receptors
Infarction
Catecholamines
Ischemia
Survival

Keywords

  • myocardial infarction
  • sphingosine 1-phosphate
  • β-adrenergic receptors
  • β-blocker

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

β1-Blockade Prevents Post-Ischemic Myocardial Decompensation Via β3AR-Dependent Protective Sphingosine-1 Phosphate Signaling. / Cannavo, Alessandro; Rengo, Giuseppe; Liccardo, Daniela; Pun, Andres; Gao, Ehre; George, Alvin J.; Gambino, Giuseppina; Rapacciuolo, Antonio; Leosco, Dario; Ibanez, Borja; Ferrara, Nicola; Paolocci, Nazareno; Koch, Walter J.

In: Journal of the American College of Cardiology, Vol. 70, No. 2, 11.07.2017, p. 182-192.

Research output: Contribution to journalArticle

Cannavo, A, Rengo, G, Liccardo, D, Pun, A, Gao, E, George, AJ, Gambino, G, Rapacciuolo, A, Leosco, D, Ibanez, B, Ferrara, N, Paolocci, N & Koch, WJ 2017, 'β1-Blockade Prevents Post-Ischemic Myocardial Decompensation Via β3AR-Dependent Protective Sphingosine-1 Phosphate Signaling', Journal of the American College of Cardiology, vol. 70, no. 2, pp. 182-192. https://doi.org/10.1016/j.jacc.2017.05.020
Cannavo, Alessandro ; Rengo, Giuseppe ; Liccardo, Daniela ; Pun, Andres ; Gao, Ehre ; George, Alvin J. ; Gambino, Giuseppina ; Rapacciuolo, Antonio ; Leosco, Dario ; Ibanez, Borja ; Ferrara, Nicola ; Paolocci, Nazareno ; Koch, Walter J. / β1-Blockade Prevents Post-Ischemic Myocardial Decompensation Via β3AR-Dependent Protective Sphingosine-1 Phosphate Signaling. In: Journal of the American College of Cardiology. 2017 ; Vol. 70, No. 2. pp. 182-192.
@article{60ddc332e1494089a35b3da904d0454b,
title = "β1-Blockade Prevents Post-Ischemic Myocardial Decompensation Via β3AR-Dependent Protective Sphingosine-1 Phosphate Signaling",
abstract = "Background Although β-blockers increase survival in patients with heart failure (HF), the mechanisms behind this protection are not fully understood, and not all patients with HF respond favorably to them. We recently showed that, in cardiomyocytes, a reciprocal down-regulation occurs between β1-adrenergic receptors (ARs) and the cardioprotective sphingosine-1-phosphate (S1P) receptor-1 (S1PR1). Objectives The authors hypothesized that, in addition to salutary actions due to direct β1AR-blockade, agents such as metoprolol (Meto) may improve post–myocardial infarction (MI) structural and functional outcomes via restored S1PR1 signaling, and sought to determine mechanisms accounting for this effect. Methods We tested the in vitro effects of Meto in HEK293 cells and in ventricular cardiomyocytes isolated from neonatal rats. In vivo, we assessed the effects of Meto in MI wild-type and β3AR knockout mice. Results Here we report that, in vitro, Meto prevents catecholamine-induced down-regulation of S1PR1, a major cardiac protective signaling pathway. In vivo, we show that Meto arrests post-MI HF progression in mice as much as chronic S1P treatment. Importantly, human HF subjects receiving β1AR-blockers display elevated circulating S1P levels, confirming that Meto promotes S1P secretion/signaling. Mechanistically, we found that Meto-induced S1P secretion is β3AR-dependent because Meto infusion in β3AR knockout mice does not elevate circulating S1P levels, nor does it ameliorate post-MI dysfunction, as in wild-type mice. Conclusions Our study uncovers a previously unrecognized mechanism by which β1-blockers prevent HF progression in patients with ischemia, suggesting that β3AR dysfunction may account for limited/null efficacy in β1AR-blocker–insensitive HF subjects.",
keywords = "myocardial infarction, sphingosine 1-phosphate, β-adrenergic receptors, β-blocker",
author = "Alessandro Cannavo and Giuseppe Rengo and Daniela Liccardo and Andres Pun and Ehre Gao and George, {Alvin J.} and Giuseppina Gambino and Antonio Rapacciuolo and Dario Leosco and Borja Ibanez and Nicola Ferrara and Nazareno Paolocci and Koch, {Walter J.}",
year = "2017",
month = "7",
day = "11",
doi = "10.1016/j.jacc.2017.05.020",
language = "English (US)",
volume = "70",
pages = "182--192",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - β1-Blockade Prevents Post-Ischemic Myocardial Decompensation Via β3AR-Dependent Protective Sphingosine-1 Phosphate Signaling

AU - Cannavo, Alessandro

AU - Rengo, Giuseppe

AU - Liccardo, Daniela

AU - Pun, Andres

AU - Gao, Ehre

AU - George, Alvin J.

AU - Gambino, Giuseppina

AU - Rapacciuolo, Antonio

AU - Leosco, Dario

AU - Ibanez, Borja

AU - Ferrara, Nicola

AU - Paolocci, Nazareno

AU - Koch, Walter J.

PY - 2017/7/11

Y1 - 2017/7/11

N2 - Background Although β-blockers increase survival in patients with heart failure (HF), the mechanisms behind this protection are not fully understood, and not all patients with HF respond favorably to them. We recently showed that, in cardiomyocytes, a reciprocal down-regulation occurs between β1-adrenergic receptors (ARs) and the cardioprotective sphingosine-1-phosphate (S1P) receptor-1 (S1PR1). Objectives The authors hypothesized that, in addition to salutary actions due to direct β1AR-blockade, agents such as metoprolol (Meto) may improve post–myocardial infarction (MI) structural and functional outcomes via restored S1PR1 signaling, and sought to determine mechanisms accounting for this effect. Methods We tested the in vitro effects of Meto in HEK293 cells and in ventricular cardiomyocytes isolated from neonatal rats. In vivo, we assessed the effects of Meto in MI wild-type and β3AR knockout mice. Results Here we report that, in vitro, Meto prevents catecholamine-induced down-regulation of S1PR1, a major cardiac protective signaling pathway. In vivo, we show that Meto arrests post-MI HF progression in mice as much as chronic S1P treatment. Importantly, human HF subjects receiving β1AR-blockers display elevated circulating S1P levels, confirming that Meto promotes S1P secretion/signaling. Mechanistically, we found that Meto-induced S1P secretion is β3AR-dependent because Meto infusion in β3AR knockout mice does not elevate circulating S1P levels, nor does it ameliorate post-MI dysfunction, as in wild-type mice. Conclusions Our study uncovers a previously unrecognized mechanism by which β1-blockers prevent HF progression in patients with ischemia, suggesting that β3AR dysfunction may account for limited/null efficacy in β1AR-blocker–insensitive HF subjects.

AB - Background Although β-blockers increase survival in patients with heart failure (HF), the mechanisms behind this protection are not fully understood, and not all patients with HF respond favorably to them. We recently showed that, in cardiomyocytes, a reciprocal down-regulation occurs between β1-adrenergic receptors (ARs) and the cardioprotective sphingosine-1-phosphate (S1P) receptor-1 (S1PR1). Objectives The authors hypothesized that, in addition to salutary actions due to direct β1AR-blockade, agents such as metoprolol (Meto) may improve post–myocardial infarction (MI) structural and functional outcomes via restored S1PR1 signaling, and sought to determine mechanisms accounting for this effect. Methods We tested the in vitro effects of Meto in HEK293 cells and in ventricular cardiomyocytes isolated from neonatal rats. In vivo, we assessed the effects of Meto in MI wild-type and β3AR knockout mice. Results Here we report that, in vitro, Meto prevents catecholamine-induced down-regulation of S1PR1, a major cardiac protective signaling pathway. In vivo, we show that Meto arrests post-MI HF progression in mice as much as chronic S1P treatment. Importantly, human HF subjects receiving β1AR-blockers display elevated circulating S1P levels, confirming that Meto promotes S1P secretion/signaling. Mechanistically, we found that Meto-induced S1P secretion is β3AR-dependent because Meto infusion in β3AR knockout mice does not elevate circulating S1P levels, nor does it ameliorate post-MI dysfunction, as in wild-type mice. Conclusions Our study uncovers a previously unrecognized mechanism by which β1-blockers prevent HF progression in patients with ischemia, suggesting that β3AR dysfunction may account for limited/null efficacy in β1AR-blocker–insensitive HF subjects.

KW - myocardial infarction

KW - sphingosine 1-phosphate

KW - β-adrenergic receptors

KW - β-blocker

UR - http://www.scopus.com/inward/record.url?scp=85021012529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021012529&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2017.05.020

DO - 10.1016/j.jacc.2017.05.020

M3 - Article

C2 - 28683966

AN - SCOPUS:85021012529

VL - 70

SP - 182

EP - 192

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 2

ER -